Cited 5 times in
In Vitro Adenosine Triphosphate-Based Chemotherapy Response Assay as a Predictor of Clinical Response to Fluorouracil-Based Adjuvant Chemotherapy in Stage II Colorectal Cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김임경 | - |
dc.contributor.author | 이강영 | - |
dc.contributor.author | 강정현 | - |
dc.date.accessioned | 2017-10-26T07:06:35Z | - |
dc.date.available | 2017-10-26T07:06:35Z | - |
dc.date.issued | 2016 | - |
dc.identifier.issn | 1598-2998 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/151610 | - |
dc.description.abstract | PURPOSE: We evaluated the usefulness of the in vitro adenosine triphosphate-based chemotherapy response assay (ATP-CRA) for prediction of clinical response to fluorouracil-based adjuvant chemotherapy in stage II colorectal cancer. MATERIALS AND METHODS: Tumor specimens of 86 patients with pathologically confirmed stage II colorectal adenocarcinoma were tested for chemosensitivity to fluorouracil. Chemosensitivity was determined by cell death rate (CDR) of drug-exposed cells, calculated by comparing the intracellular ATP level with that of untreated controls. RESULTS: Among the 86 enrolled patients who underwent radical surgery followed by fluorouracil-based adjuvant chemotherapy, recurrence was found in 11 patients (12.7%). The CDR ≥ 20% group was associated with better disease-free survival than the CDR < 20% group (89.4% vs. 70.1%, p=0.027). Multivariate analysis showed that CDR < 20% and T4 stage were poor prognostic factors for disease-free survival after fluorouracil-based adjuvant chemotherapy. CONCLUSION: In stage II colorectal cancer, the in vitro ATP-CRA may be useful in identifying patients likely to benefit from fluorouracil-based adjuvant chemotherapy. | - |
dc.description.statementOfResponsibility | open | - |
dc.format | application/pdf | - |
dc.language | English, Korean | - |
dc.publisher | Official journal of Korean Cancer Association | - |
dc.relation.isPartOf | CANCER RESEARCH AND TREATMENT | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adenocarcinoma/drug therapy* | - |
dc.subject.MESH | Adenocarcinoma/mortality | - |
dc.subject.MESH | Adenocarcinoma/pathology | - |
dc.subject.MESH | Adenocarcinoma/surgery | - |
dc.subject.MESH | Adenosine Triphosphate/metabolism | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Antimetabolites, Antineoplastic/therapeutic use* | - |
dc.subject.MESH | Carcinoembryonic Antigen/blood | - |
dc.subject.MESH | Chemotherapy, Adjuvant/methods | - |
dc.subject.MESH | Colon/pathology | - |
dc.subject.MESH | Colonoscopy | - |
dc.subject.MESH | Colorectal Neoplasms/drug therapy* | - |
dc.subject.MESH | Colorectal Neoplasms/mortality | - |
dc.subject.MESH | Colorectal Neoplasms/pathology | - |
dc.subject.MESH | Colorectal Neoplasms/surgery | - |
dc.subject.MESH | Disease-Free Survival | - |
dc.subject.MESH | Drug Screening Assays, Antitumor/methods | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Fluorouracil/therapeutic use* | - |
dc.subject.MESH | Follow-Up Studies | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Neoplasm Recurrence, Local/drug therapy* | - |
dc.subject.MESH | Neoplasm Recurrence, Local/mortality | - |
dc.subject.MESH | Neoplasm Recurrence, Local/pathology | - |
dc.subject.MESH | Neoplasm Recurrence, Local/surgery | - |
dc.subject.MESH | Neoplasm Staging | - |
dc.subject.MESH | Prospective Studies | - |
dc.subject.MESH | Rectum/pathology | - |
dc.subject.MESH | Tomography, X-Ray Computed | - |
dc.title | In Vitro Adenosine Triphosphate-Based Chemotherapy Response Assay as a Predictor of Clinical Response to Fluorouracil-Based Adjuvant Chemotherapy in Stage II Colorectal Cancer | - |
dc.type | Article | - |
dc.publisher.location | Korea | - |
dc.contributor.college | College of Medicine | - |
dc.contributor.department | Dept. of Surgery | - |
dc.contributor.googleauthor | Hye Youn Kwon | - |
dc.contributor.googleauthor | Im-kyung Kim | - |
dc.contributor.googleauthor | Jeonghyun Kang | - |
dc.contributor.googleauthor | Seung-Kook Sohn | - |
dc.contributor.googleauthor | Kang Young Lee | - |
dc.identifier.doi | 10.4143/crt.2015.140 | - |
dc.contributor.localId | A00851 | - |
dc.contributor.localId | A02640 | - |
dc.contributor.localId | A00080 | - |
dc.relation.journalcode | J00453 | - |
dc.identifier.eissn | 2005-9256 | - |
dc.relation.journalsince | 2001~ | - |
dc.identifier.pmid | 26511802 | - |
dc.relation.journalbefore | ~2001 Journal of the Korean Cancer Research Association (대한암학회지) | - |
dc.subject.keyword | Adjuvant chemotherapy | - |
dc.subject.keyword | Antitumor drug screening assays | - |
dc.subject.keyword | Colorectal neoplasms | - |
dc.contributor.alternativeName | Kim, Im Kyung | - |
dc.contributor.alternativeName | Lee, Kang Young | - |
dc.contributor.alternativeName | Kang, Jeong Hyun | - |
dc.contributor.affiliatedAuthor | Kim, Im Kyung | - |
dc.contributor.affiliatedAuthor | Lee, Kang Young | - |
dc.contributor.affiliatedAuthor | Kang, Jeong Hyun | - |
dc.citation.volume | 48 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 970 | - |
dc.citation.endPage | 977 | - |
dc.identifier.bibliographicCitation | CANCER RESEARCH AND TREATMENT, Vol.48(3) : 970-977, 2016 | - |
dc.date.modified | 2017-10-24 | - |
dc.identifier.rimsid | 45246 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.